Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT05521529
Recruiting Observational

Cushing's Syndrome Before and After Treatment (CORRECT)

NCT05521529 · tracked via the Priya Life Science Denmark tracker
Sponsor
University of Aarhus
Phase
Observational
Started
2023-02-16
Last updated
2025-04-04

Condition(s) studied

Cushing Syndrome

Investigational drug(s) / intervention(s)

no intervention, as this is an observational study

no intervention, as this is an observational study: no intervention

Study summary

The purpose of this study is to prospectively study patients with Cushing's syndrome before and after treatment, with a special emphasis on physical function, quality of life, and circadian rhythms.

The hypotheses are:

* Cushing's syndrome negatively impacts health-related quality of life (HRQoL) and physical functioning
* Cushing's syndrome is associated with altered circadian rhythms at the whole body level and in peripheral target tissues.
* These complications partially reverse following disease control.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * New (≤ 2 months) diagnosis of Cushing's syndrome (CS) of endogenous etiology: * ACTH-dependent CS * ACTH-independent CS * Age \>18 years * Written informed consent Exclusion Criteria: * Active cancer * Iatrogenic or malignant cause of CS such as adrenocortical carcinoma * Chronic heart failure (New York Heart Association class IV) * Chronic kidney disease Chronic Kidney Disease stage ≥3 (eGFR \>30 ml/min) * Liver disease in the form of cirrhosis * Deemed unable to complete the study safely by investigator

Primary outcome measure(s)

  • Change in CushingQoL-score — Baseline, 3 months after and 1 year after treatment
    Questionnaire filled out by patients

Trial sites (1)

FacilityCityRegionStatus
Department of Endocrinology and Internal Medicine Aarhus State Recruiting

More University of Aarhus trials in Denmark

Probiotic Treatment of Orthodontic Patients Recruiting
BPA vs. PEA in CTEPH Recruiting
Precision Treatment of Lumbar Spine Surgery Through Advanced Nerve Root Blockade Recruiting
IMPROVE: Circulating Tumor DNA Analysis to Optimize Treatment for Patients With Colorectal Cancer Active, not recruiting
Danish Access to Support and Help (DASH): Increasing Access to an Evidence-based Intervention for Children With ADHD and Their Parents Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05521529 on ClinicalTrials.gov ↗ ← All trials in Denmark